Efficacy and Safety of Alpelisib in Pediatric Patients with PIK3CA-Related Overgrowth Spectrum: EPIK-P1 Subgroup Analysis

Sunday, April 24, 2022

10:00 AM – 10:15 AM US MT

Location: Convention Center: 605

Publication Number: 2285.1

Denise Adams, Children's Hospital of Philadelphia, Philadelphia, PA, United States; JUAN CARLOS LOPEZ GUTIERREZ, Hospital La Paz, MADRID, Madrid, Spain; Alan Irvine, Trinity College Dublin, Dublin, Dublin, Ireland; Jordan R. Hansford, The Royal Children's Hospital, Parkville, Victoria, Australia; Nii Ankrah, Novartis Pharmaceuticals, East Hanover, NJ, United States; Athanasia Papadimitriou, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland; Antonia Ridolfi, novartis, RUEIL MALMAISON, Ile-de-France, France; Sabino Vesce, Novartis Pharma, Basel, Switzerland, Lausanne, Vaud, Switzerland; Guillaume Canaud, Université de Paris, Institut Necker-Enfants Malades (U1151), Hôpital Necker-Enfants Malades, Paris, Centre, France

Presenting Author(s)

Denise M. Adams, MD
Professor of Pediatrics
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States

Participants should be aware of the following financial/non-financial relationships:

Denise M. Adams, MD: ● novartis (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Advisory Committee).

JUAN CARLOS LOPEZ GUTIERREZ, Associate Professor: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Alan Irvine, MD DSc: ● Novartis (Currently Ongoing) (Products/Services: Consultant, Advisory Committee).
● Novartis (Currently Ongoing) (Products/Services: Consultant, Advisory Committee).

Jordan R. Hansford, BScH MSc MBBS FRACP: ● Bayer Australia (Ended In the Past 24 Months) (Products/Services: Advisory Committee).

Nii Ankrah, medical degree: ● Novatis Pharmaceutical (Currently Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).

Athanasia Papadimitriou, University of Siena, Faculty of Medicine, School of Medicine and Surgery: ● Novartis AG (Currently Ongoing) (Products/Services: Employment with an ineligible company).

Antonia Ridolfi, Msc in medical statistcs: ● NOVARTIS PHARMA (Currently Ongoing) (Products/Services: Employment with an ineligible company).

Sabino Vesce, PhD: ● Novartis AG (Currently Ongoing) (Products/Services: Employment with an ineligible company).

Guillaume Canaud, MD, PhD: ● BridgeBio (Currently Ongoing) (Products/Services: Consultant).
● Novartis (Currently Ongoing) (Products/Services: Consultant, Advisory Committee, Speaker Honorarium including speakers bureau, symposia, and expert witness, Intellectual Property including patent beneficiary and royalties).
● Vaderis (Currently Ongoing) (Products/Services: Consultant, Advisory Committee).